Diagnostic and Therapeutic Strategy Updates of Rare Oncogenic Mutations in Chinese Society of Clinical Oncology Guidelines on Diagnosis and Treatment of Non-small Cell Lung Cancer (2023 Edition)
10.3971/j.issn.1000-8578.2023.23.1022
- VernacularTitle:《2023 CSCO非小细胞肺癌诊疗指南》罕见靶点诊疗更新
- Author:
Yingge LI
1
;
Yi DONG
;
Shuyang YU
;
Yingmei WEN
;
Qibin SONG
;
Yi YAO
Author Information
1. Cancer Center, Renmin Hospital of Wuhan University, Wuhan 430060, China
- Publication Type:Research Article
- Keywords:
NSCLC;
Rare oncogenic mutations;
Diagnosis and therapy;
Guidelines updates;
CSCO
- From:
Cancer Research on Prevention and Treatment
2023;50(12):1232-1236
- CountryChina
- Language:Chinese
-
Abstract:
The Chinese Society of Clinical Oncology (CSCO) issued the new version of the guidelines on diagnosis and treatment of NSCLC in April 2023.The new version updated the diagnostic and therapeutic strategy of rare oncogenic mutations, including ROS1 fusion, BRAF V600E mutation, NTRK fusion, MET exon 14 skipping mutation, RET fusion, and EGFR exon 20 insertion mutation, in NSCLC.This review will interpret the most important updates in the guidelines 2023 regarding the diagnosis as well as first-line and post-line therapies of these rare oncogenic mutations.
